(Reuters) -Medical equipment maker Thermo Fisher Scientific on Wednesday cut its annual profit forecast for the second straight quarter, hurt by lower-than-expected demand for its services used to make therapeutics, vaccines and analytical tools.

The company now expects adjusted profit of $21.50 per share in 2023, compared with its previous forecast of $22.28 to $22.72 per share.

The manufacturer of medical products has been expanding its range of services through deals in recent years, in a bid to become a one-stop shop for its biotech and large pharmaceutical clients.

Thermo Fisher reported a quarterly adjusted profit of $5.69 per share, compared with analysts' estimates of $5.61 per share, according to LSEG data.

The company's shares fell 2.2% in premarket trading.

(Reporting by Bhanvi Satija in Bengaluru; Editing by Shinjini Ganguli and Shounak Dasgupta)